Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
about
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentPhase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP studyOral fluoropyrimidines among the new drugs for patients with metastatic breast cancerA phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancerInduction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck.Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.Taxanes in the treatment of breast cancer: a prodigy comes of age.Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patientsClinical trials in the era of personalized oncology.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342Paclitaxel impairs adipose stem cell proliferation and differentiation.Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer.Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.The role of taxanes in the treatment of breast cancer.Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.Current approaches to the management of Her2-negative metastatic breast cancer.Taxanes for the treatment of metastatic breast cancer.Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.Weekly docetaxel in the treatment of metastatic breast cancer.Ixabepilone: a new microtubule-targeting agent for breast cancer.Taxane-induced arthralgia and myalgia: A literature review.Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group.Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience.Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.Therapeutic options for metastatic breast cancer
P2860
Q28073057-18CF6E98-1760-41F4-AD3D-85DBF1277D4EQ28359347-36A190AE-DCA9-457D-8DF1-6DC9CFBE4757Q28366029-7F5F8771-804B-448B-A5BF-2E229A025DB1Q33244593-EFAF2DA5-039F-40B6-9807-2E97802F65B0Q33335541-8FE53D58-7751-4093-A30B-DD2ED5CE7492Q33335622-FF176C2C-781A-4DE4-BD3D-CADFD968F137Q33336786-C5522D25-9794-498D-B8D4-D6BF615C46CBQ33539951-592BFF46-2CAB-4222-9CB8-3833ED9447FAQ33984071-214D908E-F28F-4D6E-9A73-93E97C27C9FBQ34182224-6AFC1C6A-00CE-40EF-AD7E-F31DD596ADACQ34205196-5F49DD2B-E365-4776-82AB-69548AAAD4A1Q34713757-4EC0F96D-B3EF-4CD2-BF6A-C0822E3D1658Q35555963-5CB10757-C050-499A-81A6-12C850CBDEFFQ35599769-05C965F9-3D22-4440-A077-F09D9B0B0FDDQ35633680-49C6744F-B236-4897-B3CA-E42DB31E0A34Q35642332-01188E75-64AE-404C-ACF7-38BE029086AFQ35691756-ABEAEF48-A52C-4677-BC1D-33CA2788095CQ36035404-CBEA12CE-7294-4A60-B393-732D2AD2D4E6Q36163956-57152828-7FB9-4DC2-91BA-CAE83EF9A868Q36197026-165B6C5A-4E60-4633-B572-0FB9903267F5Q36245461-A6662C1C-529E-4240-BDC4-3DB19E041DE7Q36364762-6BDD5964-88B4-4AF9-BCCF-CFBCAB776005Q36697132-FE7957D2-459C-4C8F-BE68-D74F8929AE96Q36781543-5A4FCF34-0C25-47DC-990B-9378A76E2375Q37052871-B10AF030-7480-4FF9-A848-549B310202B6Q37159488-B7F3416B-9AC5-4D9A-9A5D-AA0077EBA94EQ38711952-1E76A37B-ABBD-4677-9A7D-CF840E79F79DQ40455268-D88CB0BD-7AE6-4B88-B42F-1B86622FA2C8Q40603376-AF21D228-5484-417E-8F3C-A3F7CDA3F92FQ40647458-53B97327-10C2-465D-B48E-56C42169B16FQ40778601-C855E9A3-51F3-4541-AE1B-B7D6588E74A3Q42536982-200C8C2F-21EF-43F3-9A8E-B953E5105D2DQ43639604-A1C14835-74E6-4762-BA11-ABAF6DA8B1BAQ45984305-D978E3E0-24DB-40B3-ABBE-CA786CCDDD89Q52207123-19A08836-A668-4518-A0D6-78114E7A65F4Q54024093-9636D2C2-C21B-4B51-B53C-E8DFD514AD51Q54672469-7716241C-FD7A-4B9F-B83D-77969CBDBFFFQ57142375-230DFC59-5F61-4D76-A4DB-A82E3C73C92D
P2860
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
description
1995 nî lūn-bûn
@nan
1995 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Phase II trial of paclitaxel b ...... for metastatic breast cancer.
@ast
Phase II trial of paclitaxel b ...... for metastatic breast cancer.
@en
type
label
Phase II trial of paclitaxel b ...... for metastatic breast cancer.
@ast
Phase II trial of paclitaxel b ...... for metastatic breast cancer.
@en
prefLabel
Phase II trial of paclitaxel b ...... for metastatic breast cancer.
@ast
Phase II trial of paclitaxel b ...... for metastatic breast cancer.
@en
P2093
P1476
Phase II trial of paclitaxel b ...... for metastatic breast cancer.
@en
P2093
A D Seidman
A Tiersten
T Gilewski
P304
P356
10.1200/JCO.1995.13.10.2575
P407
P577
1995-10-01T00:00:00Z